POS1110 RISING TREND OF OBESITY PREVALENCE IN PATIENTS ADMITTED FOR SLE FLARE-UPS: A FIVE-YEAR ANALYSIS USING THE NIS DATABASE
Authors: R. Ali, H. Al-Sudani, I. Tskhakaia, A. Lau, F. Rodriguez, S. Abdollahi, I. Tan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic Lupus Erythematosus (SLE), a chronic autoimmune condition, is known for its diverse manifestations and comorbidities, including obesity. The pathogenesis of systemic lupus erythematosus (SLE) is complex and includes genetic and environmental factors. Obesity has been associated with an increased risk of autoimmune diseases. Adipose tissue can secrete adipokines, complement components, and other pro-inflammatory mediators. Additionally, it can increase estrogen levels, which can accelerate SLE disease activity.[1-4] This indicates the importance of recognizing obesity as an important comorbidity when evaluating patients with SLE. <h3>Objectives:</h3> This study aims to examine the trend in the prevalence of obesity among patients admitted for SLE flare-ups from 2016 to 2020, utilizing the National Inpatient Sample (NIS) database and ICD-10 codes. <h3>Methods:</h3> A comprehensive retrospective analysis was undertaken utilizing the National Inpatient Sample (NIS) database. The study specifically focused on patients aged 18 and above who underwent elective admissions for Systemic Lupus Erythematosus (SLE) flare-ups. The objective was to investigate and assess the annual prevalence of obesity within this patient cohort over a span of five years. By leveraging the extensive data provided by the NIS database and employing the International Classification of Diseases, Tenth Revision (ICD-10) codes, the study aimed to elucidate the evolving trends in obesity prevalence among individuals electively admitted for SLE flare-ups from 2016 to 2020. This comprehensive approach enhances our understanding of the relationship between SLE flare-ups and obesity, providing valuable insights for future clinical management and preventive strategies. <h3>Results:</h3> The study illuminates an upward trajectory in the prevalence of obesity among patients admitted for Systemic Lupus Erythematosus (SLE) flare-up. In 2016, a notable 10.3% of such patients, totaling 5,184 individuals, were identified as obese. This percentage exhibited a steady ascent, reaching 12.7% in 2017 (n = 5,543). The subsequent year, 2018, witnessed a slight decline to 12% (n = 5,950), only to experience a marginal uptick to 12.1% in 2019 (n = 5,578). However, the most substantial surge occurred in 2020, with a noteworthy 14.4% prevalence of obesity, encompassing 5,028 patients.[Figure 1] <h3>Conclusion:</h3> The increasing trend of obesity prevalence among SLE flare-up admissions over the study period highlights an important aspect of patient health that warrants attention in the management of SLE. The gradual rise, particularly the notable increase in 2020, suggests a growing need to incorporate obesity management into the holistic care of SLE patients. These findings underscore the importance of recognizing and addressing obesity as a comorbid condition in SLE, which may influence disease progression and patient outcomes. <h3>REFERENCES:</h3> [1] Cao H: Adipocytokines in obesity and metabolic disease. <i>J Endocrinol</i> 2014, 220(2):T47–59. [PMC free article] [PubMed] [Google Scholar] [2] Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. <i>J Clin Endocrinol Metab</i> 2004, 89(6):2548–2556. [PubMed] [Google Scholar] [3] Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O: What's new in our understanding of the role of adipokines in rheumatic diseases? <i>Nat Rev Rheumatol</i> 2011, 7(9):528–536. [PubMed] [Google Scholar] [4] Nelson LR, Bulun SE: Estrogen production and action. <i>J Am Acad Dermatol</i> 2001, 45(3 Suppl):S116–124. [PubMed] [Google Scholar] <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>